Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 22, 2025, discloses a material definitive agreement entered into by Catheter Precision, Inc. (the "Company") and its subsidiary, Cardionomix, Inc. The filing also provides preliminary financial results for the quarter ended March 31, 2025.
Key Financial Metrics and Transaction Terms
- Revenue: Preliminary total revenues for the quarter ended March 31, 2025, were approximately $142,000.
- Transaction Consideration: The acquisition of assets from Cardionomic, Inc. involves the issuance of 1,000,000 restricted shares of Company common stock and a promissory note of $1.5 million.
- Debt Terms: The promissory note carries simple interest at 4% per annum, with no principal or interest payments due until maturity, which is three years from issuance.
- Liquidity: The Company states it does not have sufficient liquidity to fund its business for the next three to six months without obtaining additional financing or entering into a strategic transaction.
Material Changes and Operational Updates
- Revenue Growth: Quarterly revenue increased by 73% compared to the $82,000 reported in the quarter ended March 31, 2024.
- Asset Acquisition: The Company is acquiring patents and trademarks related to the Cardiac Pulmonary Nerve Simulation (CNPS) System for the treatment of acute decompensated heart failure. The assets are being purchased on an "AS IS" and "WHERE IS" basis with limited representations.
- Internal Controls: The Company disclosed that its internal controls and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.
Outlook, Risks, and Contingencies
- Financing Needs: The subsidiary, Cardionomix, will require external funding to develop the acquired assets. Future financing is expected to dilute the Company's ownership interest, though it is expected to remain a majority-owned consolidated entity.
- Closing Conditions: The transaction is subject to conditions including NYSE American approval for the listing of the share consideration and must close by July 21, 2025, or the agreement will terminate.
- Development Risks: Pilot studies of the acquired technology identified challenges including nerve fatigue, unstable hemodynamics, and the need for device modifications. There is no guarantee of FDA approval or successful commercialization.
- Forward-Looking Statements: The filing contains numerous risks regarding the competitive medical device industry, supply chain disruptions, and the potential failure to achieve profitability.
Investor Verification Checklist
- Verify the status of the NYSE American listing approval for the 1,000,000 shares issued as consideration.
- Confirm the timeline and terms of the anticipated external financing for the Cardionomix subsidiary.
- Review the remediation plan for the material weaknesses in internal controls identified in the 2024 Form 10-K.
- Assess the specific technical modifications required for the CNPS System based on the pilot study limitations mentioned.
- Monitor the July 21, 2025, deadline for the closing of the asset purchase agreement.